revaluation on basis of less dilution19 Aug 2020 15:20
there is significant discount here at the moment for 'we don't have a done and dusted finance package' but I also suspect discount for 'we don't know how diluted we are going to be'. Aside from the obvious discount of 'we've only just heard of HZM should we buy in?' where people just don't know this is The Next Big Thing (AIM stock to rise).
If on the 'we don't know how diluted we are going to be' we surprise on the upside - i.e. very little dilution or it is constrained at project level or rolled up into some other kind of deal - we could see a double re-rate and my estimates become far too pessimistic near term. To stay grounded I always worked on 2.5bn shares equating to 10p at 250m mcap which I thought might be a realistic post finance price (initially, when we start building).
Now if little or no dilution happens at 1.6bn shares (including options) gives 15.6p.
The difference is even more obvious with my 'at production' estimate. If I estimate £500m mcap at production, at my previous shares in issue estimate 20p (perhaps pessimistic again but prefer to stay grounded). At that point equivalent would be 31.2p.
All illustrative only above but it does show the importance of a 'good deal' for existing shareholders and given the length of the process, if the BOD have been astute and diligent that's what they've been hammering out so we end with the top end of the above not the bottom end. Find out in a few months time!
Speaking personally, for my plans, big difference to me between 10 and 15.6p in the near term, and also between 20 and 31.2p in 2023. Probably others also.